Clinical Trial Update: A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of ramucirumab and pembrolizumab in gastric/GEJ adenocarcinoma, non-small cell lung cancer, urothelial carcinoma, and b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Biliary Tract Cancer
• Gastric Adenocarcinoma
• Non-small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• Cyramza (ramucirumab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Status: COMPLETED | Results posted: 2024-07-31